(n=6) remain disease-free more than two years after treatment; 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at ...

Talzenna-Xtandi secures an FDA label expansion as the cancer treatment paradigm shifts towards the use of mutation-specific ...

Adding darolutamide to ADT and RT improved metastasis-free survival, but questions persist ...

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen ...

Darolutamide improved metastasis-free survival alongside hormone therapy and radiotherapy in very high-risk prostate cancer.

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

Prostate cancer with ocular metastasis is extremely rare, especially as an isolated visceral oligometastasis. Examination and ultrasound identified a choroidal mass suspected to be uveal melanoma.

Yesterday, the United States Food and Drug Administration (FDA) announced the approval of a new immune-based approach for ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

The approval makes the PARP inhibitor available earlier in the line of treatment for some patients with metastatic disease.

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...